Clinical Presentation of Endometrioid Epithelial Ovarian Cancer with Concurrent Endometriosis: A Multicenter Retrospective Study

Myong Cheol Lim, Kyoung-Chul Chun, Kyoung‐Chul Chun, So‐Jin Shin, So-Jin Shin, In Ho Lee, In-Ho Lee, Kyung Taek Lim, Chi Heum Cho, Chi‐Heum Cho, Sang-Yoon Park, Sang‐Yoon Park, Joo-Hyun Nam
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2010 · vol. 19(2) , pp. 398–404 · doi:10.1158/1055-9965.epi-09-0750 · PMID:20086106 · W2139093347
article OA: bronze CC0 ⤵ 25 in-corpus citations
📄 Open PDF View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-07 ⓘ

This study of 221 endometrioid epithelial ovarian cancer patients found pelvic pain and gastrointestinal symptoms were most common, with dyspareunia and dysmenorrhea more frequent in those with concurrent endometriosis.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

BACKGROUND: Endometrioid epithelial ovarian cancer (EEOC) is frequently diagnosed in conjunction with endometriosis and is suggested to arise during the process of endometriosis. This study evaluates the clinical manifestations, including endometriosis-related symptoms and their relationships according to the coexistence of endometriosis. METHODS: Using medical records, a retrospective analysis was conducted on 221 patients treated for EEOC at four tertiary educational hospitals between 2000 and 2008. The initial presenting symptoms, particularly those related to endometriosis, were examined in relation to the coexistence of endometriosis or other clinical variables. RESULTS: Endometriosis was identified in 82 (37.1%) of the 221 patients with EEOC. The most common symptoms were pelvic pain followed by gastrointestinal symptoms, palpable mass, abdominal distension, vaginal bleeding, and newly developed or exacerbated dysmenorrhea (18.1%) and dyspareunia (13.6%). Notably, dysmenorrhea and dyspareunia were frequently observed in patients with endometriosis. Among 210 patients identified with pretreatment serum CA-125, 54 (25.7%) displayed normal CA-125 levels (<35 units/mL) and 23.3% and 29.9% of patients without and with endometriosis had normal CA-125 levels, respectively (P = 0.381). Additionally, 32.6% of the patients with early-stage EEOC displayed normal CA-125 levels. CONCLUSIONS: In this large series of patients with EEOC, the main presenting symptoms were pelvic pain followed by gastrointestinal symptoms, palpable mass, abdominal distension, vaginal bleeding, and newly developed or exacerbated dysmenorrhea and dyspareunia. Dyspareunia and dysmenorrhea were more frequently detected in patients with endometriosis. Normal CA-125 levels cannot be applied as a marker to exclude EEOC, particularly at the early stages.

My notes (saved in your browser only)

Condition tags

endometriosisdysmenorrheadyspareunia

MeSH descriptors

Carcinoma, Endometrioid Endometriosis Ovarian Neoplasms Adult Aged CA-125 Antigen CA-125 Antigen Carcinoma, Endometrioid Carcinoma, Endometrioid Carcinoma, Endometrioid Endometriosis Endometriosis Endometriosis Female Humans Middle Aged Ovarian Neoplasms Ovarian Neoplasms Ovarian Neoplasms Retrospective Studies

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (45)

Cited by (25)

Source provenance

europepmc
last seen: 2026-07-02T06:07:54.402228+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-13T22:17:18.915199+00:00
License: CC0 · commercial use OK